91,099 Shares in Krystal Biotech, Inc. $KRYS Bought by William Blair Investment Management LLC

Key Points

• William Blair Investment Management LLC purchased 91,099 shares of Krystal Biotech, valued at approximately $12.5 million, during the second quarter.
• Analysts have set new price targets for Krystal Biotech, with Bank of America raising their target from $182 to $255, maintaining a "buy" rating.
• As of the latest quarter, institutional investors own 86.29% of Krystal Biotech, indicating significant interest from large investment funds.

William Blair Investment Management LLC bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 91,099 shares of the company's stock, valued at approximately $12,522,000. William Blair Investment Management LLC owned about 0.32% of Krystal Biotech at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. CWM LLC grew its stake in Krystal Biotech by 7.2% during the 2nd quarter. CWM LLC now owns 1,583 shares of the company's stock worth $218,000 after buying an additional 107 shares during the last quarter. Aberdeen Group plc grew its stake in Krystal Biotech by 190.9% during the 2nd quarter. Aberdeen Group plc now owns 108,518 shares of the company's stock valued at $14,917,000 after purchasing an additional 71,217 shares during the last quarter. Vontobel Holding Ltd. grew its stake in Krystal Biotech by 13.9% during the 2nd quarter. Vontobel Holding Ltd. now owns 3,075 shares of the company's stock valued at $423,000 after purchasing an additional 375 shares during the last quarter. Maryland State Retirement & Pension System grew its stake in Krystal Biotech by 1.7% during the 2nd quarter. Maryland State Retirement & Pension System now owns 7,474 shares of the company's stock valued at $1,027,000 after purchasing an additional 123 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Krystal Biotech by 15.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,116 shares of the company's stock valued at $153,000 after purchasing an additional 152 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Bank of America boosted their price target on Krystal Biotech from $182.00 to $255.00 and gave the company a "buy" rating in a research note on Friday. Weiss Ratings reiterated a "hold (c)" rating on shares of Krystal Biotech in a research note on Wednesday, October 8th. Citigroup reiterated a "neutral" rating and set a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Guggenheim set a $224.00 price target on Krystal Biotech and gave the company a "buy" rating in a research note on Friday. Finally, Chardan Capital lowered their target price on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a research note on Friday, August 22nd. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $223.00.

Krystal Biotech Stock Up 3.0%

Shares of KRYS opened at $195.96 on Tuesday. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $207.84. The company has a market capitalization of $5.67 billion, a price-to-earnings ratio of 39.83 and a beta of 0.64. The stock's 50-day moving average price is $161.87 and its 200-day moving average price is $151.27.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. The firm had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. As a group, equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.